LYMPHOCYTES from patients with malignant diseases can be differentiated from those of healthy donors or donors with non-malignant disorders by changes in the structuredness of cytoplasmic matrix (SCM) induced by cancer basic protein (CaBP) and phytohaemagglutinin (Cercek, Cercek and Franklin, 1974; . Cancer basic protein is recognized by lymphocytes from all patients with different malignant diseases and is therefore a nonspecific " antigen ". The SCM test thus offers an aid in diagnosing whether a disease is of a malignant nature or not and in monitoring the success of surgical removal of malignant tissues (Cercek and Cercek, 1975) .
However, lymphocyte responses to CaBP and PHA do not reveal the type or site of the tumour. To explore if the SCM test could be made tumour specific, we have started a study in which lymphocytes from donors with different malignant disorders and those from healthy donors are challenged or " baited " with cell associated, tissue specific antigens. We found that in the following modification of the SCM test lymphocytes from donors with different malignant diseases decreased the SCM only when challenged by specific tumour tissues.
The technique of measurement of the SCM and the preparation of lymphocytes for this test are the same as those described before (Cercek, Cercek and Ockey, 1973; mata responded only to the carcinoma of breast tissue, and lymphocytes from a patient with squamous cell carcinoma of bronchus responded only to the carcinoma of lung tissue etc. Lymphocytes from healthy donors did not respond to any normal or malignant tissue after up to 60 min incubation.
These preliminary data indicate that there are tumour tissue specific " antigens " different from CaBP, which lymphocytes recognize and respond to with a decrease in the SCM if brought into contact or " baited " with tumour cells similar to those which they have already encountered in the body of the donor. Further studies with a variety of tumour tissues, tumour and normal cell suspensions, as well as those from tissues affected with inflammatory and other diseases are in progress.
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